196 related articles for article (PubMed ID: 26621833)
1. Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation.
Liu YH; Tsang JY; Ni YB; Hlaing T; Chan SK; Chan KF; Ko CW; Mujtaba SS; Tse GM
Oncotarget; 2016 Jan; 7(2):1464-76. PubMed ID: 26621833
[TBL] [Abstract][Full Text] [Related]
2. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
3. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.
Kadletz L; Kenner L; Wiebringhaus R; Jank B; Mayer C; Gurnhofer E; Konrad S; Heiduschka G
Pathol Res Pract; 2019 Dec; 215(12):152698. PubMed ID: 31706685
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma.
Kwon SY; Bae YK; Gu MJ; Choi JE; Kang SH; Lee SJ; Kim A; Jung HR; Kang SH; Oh HK; Park JY
Histopathology; 2014 Apr; 64(5):647-59. PubMed ID: 24117859
[TBL] [Abstract][Full Text] [Related]
6. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
7. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.
Cao YW; Li WQ; Wan GX; Li YX; Du XM; Li YC; Li F
J Exp Clin Cancer Res; 2014 Nov; 33(1):97. PubMed ID: 25420528
[TBL] [Abstract][Full Text] [Related]
8. Doublecortin-like kinase 1-positive enterocyte - a new cell type in human intestine.
Leppänen J; Helminen O; Huhta H; Kauppila JH; Miinalainen I; Ronkainen VP; Saarnio J; Lehenkari PP; Karttunen TJ
APMIS; 2016 Nov; 124(11):958-965. PubMed ID: 27677532
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
[TBL] [Abstract][Full Text] [Related]
11. [Expression of doublecortin-like kinase 1 in human gastric cancer and its correlation with prognosis].
Meng QB; Yu JC; Kang WM; Ma ZQ; Zhou WX; Li J; Zhou L; Cao ZJ; Tian SB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Dec; 35(6):639-44. PubMed ID: 24382242
[TBL] [Abstract][Full Text] [Related]
12. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Lai BS; Tsang JY; Poon IK; Shao Y; Chan SK; Tam FK; Cheung SY; Shea KH; Tse GM
Oncologist; 2020 Sep; 25(9):e1318-e1329. PubMed ID: 32472950
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation.
Mohanty SK; Kim SA; DeLair DF; Bose S; Laury AR; Chopra S; Mertens RB; Dhall D
Mod Pathol; 2016 Aug; 29(8):788-98. PubMed ID: 27125358
[TBL] [Abstract][Full Text] [Related]
15. Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase.
Weygant N; Ge Y; Qu D; Kaddis JS; Berry WL; May R; Chandrakesan P; Bannerman-Menson E; Vega KJ; Tomasek JJ; Bronze MS; An G; Houchen CW
Cancer Res; 2016 Jul; 76(14):4090-9. PubMed ID: 27287716
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
17. A dual prognostic role for the TGFβ receptors in human breast cancer.
Hachim IY; Hachim MY; López-Ozuna VM; Ali S; Lebrun JJ
Hum Pathol; 2016 Nov; 57():140-151. PubMed ID: 27445263
[TBL] [Abstract][Full Text] [Related]
18. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
[TBL] [Abstract][Full Text] [Related]
20. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
